Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal?

Biohaven (BHVN) drew fresh investor attention after announcing a global licensing and collaboration agreement that gives SK Biopharmaceuticals exclusive worldwide rights to its Kv7 ion channel platform, led by opakalim for focal epilepsy.

The announcement arrives after a strong run in Biohaven’s share price, with a 90 day share price return of 52.12% and a year to date share price return of 42.16%, while the 1 year total shareholder return is roughly flat at 0.13%.

Scan how licensing driven stories like Biohaven's compare with other high potential biopharma opportunities by reviewing our hand picked 19 high quality undiscovered gems in the sector.

After Biohaven's sharp move on the licensing news and a share price that has already rerated over the past quarter, the key issue now is timing. Does the current level already reflect the deal, or is patience more sensible?

Preferred Price to Book Multiple of 190.4x: Is It Justified For Biohaven?

On traditional valuation metrics, Biohaven looks very expensive. The stock trades on a price to book ratio of 190.4x compared with a peer average of 11.4x and a broader US biotechs industry average of 2.5x.

The P/B multiple compares Biohaven's market value with its book value, which is essentially the net assets on its balance sheet. For asset light biopharma companies with limited current revenue and ongoing R&D spend, investors often focus less on today’s book value and more on the potential of the pipeline and future cash flows.

In Biohaven's case, the premium multiple suggests investors are assigning a much higher value to its development programs and future prospects than the balance sheet alone would support. However, analysts also expect Biohaven to remain unprofitable over the next 3 years, and the company currently reports no meaningful revenue and a net loss of $586.841m, which means the valuation rests heavily on future execution rather than current earnings power.

Compared with the US biotechs industry P/B of 2.5x, Biohaven's 190.4x multiple is extremely high. It also sits far above the 11.4x average for its direct peer group, which reinforces how much optimism is already embedded into the share price relative to sector norms.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 190.4x (OVERVALUED)

However, Biohaven's story could be knocked off course if key clinical trials disappoint, or if fresh equity raises dilute existing shareholders at current valuation levels.

Find out about the key risks to this Biohaven narrative.

Another View On Biohaven Using Our DCF Model

The P/B comparison points to Biohaven looking very expensive. Yet the SWS DCF model suggests a fair value of $73.03 per share versus a market price of $15.41, which implies the stock trades roughly 78.9% below that estimate. Which lens do you treat as more persuasive?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Biohaven for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such mixed signals around Biohaven, it helps to move quickly and weigh the facts for yourself. Start by weighing its 2 key rewards and 5 important warning signs

Looking for more investment ideas beyond Biohaven?

Do not stop with Biohaven. Use these hand picked stock ideas to broaden your watchlist and spot opportunities you might otherwise miss.

• Target stability first and scan companies that score well on resilience and downside protection through the 75 resilient stocks with low risk scores.
• Hunt for quality at a reasonable price by reviewing companies that screen as attractively valued in the 45 high quality undervalued stocks.
• Build a watchlist of financially robust businesses by checking out companies highlighted in the list of solid balance sheet and fundamentals (52 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com